Fangfang Jin
Overview
Explore the profile of Fangfang Jin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
852
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jin F, Cheng N, Wang L, Ye B, Xia J
J Chem Inf Model
. 2025 Mar;
PMID: 40082068
Synonymous mutations, once considered to be biologically neutral, are now recognized to affect protein expression and function by altering the RNA splicing, stability, or translation efficiency. These effects can contribute...
2.
Li Y, Jin F, Li Y, Li Y, Wang Y, Yang X
Front Cell Infect Microbiol
. 2025 Feb;
15:1474127.
PMID: 39958931
Objectives: The goal of this study is to evaluate the analytical and clinical performance of a new human immunodeficiency virus antigen and antibody (HIV Ag/Ab) test using light-initiated chemiluminescent assay...
3.
Yang P, Liang G, Ni Y, Chu X, Zhang X, Wang Z, et al.
J Transl Med
. 2025 Jan;
23(1):126.
PMID: 39875915
Growing evidence implicates that intratumoral microbiota are closely linked to cancer progression; however, research on the role of these microbiota in the development of gastric cancer remains limited. Here, using...
4.
Jin F, Wei X, Liu Y, Tang L, Ren J, Yang J, et al.
Biomaterials
. 2025 Jan;
317:123091.
PMID: 39778270
Acute myeloid leukemia (AML) presents significant treatment challenges due to the severe toxicities and limited efficacy of conventional therapies, highlighting the urgency for innovative approaches. Organelle-targeting therapies offer a promising...
5.
Ren J, Huang J, Yang Z, Sun M, Yang J, Lin C, et al.
J Exp Clin Cancer Res
. 2024 Jun;
43(1):176.
PMID: 38909249
Background: Acute myeloid leukemia (AML) is a hematopoietic malignancy with poor outcomes, especially in older AML patients. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is considered a promising anticancer drug because...
6.
Qian H, Fu Y, Guo M, Chen Y, Zhang D, Wei Y, et al.
Mol Ther
. 2024 Jun;
32(7):2423-2424.
PMID: 38906153
No abstract available.
7.
Yang P, Sun Y, Wang C, Li Z, Han Y, Gong J, et al.
Clin Transl Med
. 2024 May;
14(5):e1677.
PMID: 38760892
No abstract available.
8.
Wei Y, Zhang D, Shi H, Qian H, Chen H, Zeng Q, et al.
Genes Dis
. 2024 Apr;
11(4):101041.
PMID: 38560503
Pyruvate dehydrogenase kinase 1 (PDK1) phosphorylates the pyruvate dehydrogenase complex, which inhibits its activity. Inhibiting pyruvate dehydrogenase complex inhibits the tricarboxylic acid cycle and the reprogramming of tumor cell metabolism...
9.
Liu J, Li J, Jin F, Li Q, Zhao G, Wu L, et al.
NAR Cancer
. 2024 Feb;
6(1):zcae008.
PMID: 38406264
Radiation therapy (RT) is one of the primary treatment modalities of cancer, with 40-60% of cancer patients benefiting from RT during their treatment course. The intrinsic radiosensitivity or acquired radioresistance...
10.
Wu W, Huang J, Han P, Zhang J, Wang Y, Jin F, et al.
Molecules
. 2023 Nov;
28(22).
PMID: 38005352
Alzheimer's disease (AD) is a prevalent neurodegenerative disorder. With the aging population and the continuous development of risk factors associated with AD, it will impose a significant burden on individuals,...